Shortly after in 2011, sales began to decline due to the development of a more effective treatment, ranibizumab (a monoclonal antibody, Novartis) being developed and sold, and the off-label use of the cheaper Bevacizumab.
Shortly after in 2011, sales declined because of the emergence of a more potent treatment, ranibizumab (a monoclonal antibody, Novartis), that was developed and made available, along with the off-label use of the less costly Bevacizumab.